Given the similarities between the aetiologies of various chronic kidney diseases, we estimate that our lead formulation is applicable to more than 10 different diseases without any modification. After initial success for 1 or 2 indications, we aim to prove the value of our lead formulation in as many of these diseases, which together make up for about 85% of all CKD patients.